An innovative biotools company puts an experienced bioentrepreneur at the helm
LOWER GWYNEDD, Pa.–(BUSINESS WIRE)–ChromaTanTM announced today that Dr. Rajiv Datar has been appointed the new President & CEO of the company. A bioentrepreneur with over 25 years C-level experience in bioprocessing and drug development, Dr. Datar succeeds Oleg Shinkazh, the Founder of ChromaTan, who will continue as its Chief Technology Officer to focus on advancing the field of integrated continuous bioprocessing.
Recently, Dr. Datar was the Co-Founder & CEO of a biotech startup that developed an early-stage asset, which was acquired by a Global Top-5 Biopharma Company.
“It was immediately clear that Dr. Datar was the right fit,” said Steve Carpenter, Chair of the Board of Directors’ compensation committee. “The board of ChromaTan is so pleased to have Dr. Datar join the company in this role. We’ve been aware of his work and experience. Several of Dr. Datar’s projects in which he either participated or headed, are currently in the market either as bioprocessing equipment or as life-saving drugs and we know he will lead us into a new era.”
“ChromaTan has reached an inflection point in its journey,” said Oleg Shinkazh, Founder & CTO. “We doubled our headcount in 2023 in preparation of the official launch of our bench-top, continuous countercurrent tangential chromatography platform, KascadeTM, at the 2023 Bioprocess international Conference and Exhibition in Boston, MA. We’re excited to embrace the leadership and the dual experiences of biopharmaceutical development and bioprocessing that Dr. Datar brings to ChromaTan.”
Dr. Datar completed his post-Doctoral studies in Biochemical Engineering at the Massachusetts Institute of Technology, Cambridge, MA, and his Doctoral studies in Bioprocess Technology from KTH Royal Institute of Technology, Stockholm, Sweden. His work experience spans Fortune 100 and 500 companies, and four biotech and bioprocessing startups.
“ChromaTan’s vision is to revolutionize bioprocessing productivity through transformational next generation biomanufacturing solutions,” said Dr. Datar. “Our aim is to empower biopharmaceutical manufacturers with the first-ever, columnless, single-use continuous chromatography platform for the cost-effective production of life-savings therapies, and this is about as exciting an opportunity as they come to achieving this goal.”
ChromaTanTM, a privately held bioprocessing and biotools company, has created a novel purification system called Continuous Countercurrent Tangential Chromatography (CCTC). It has been shown to cut in half the cost of biologics purification while offering significantly higher yields for gene therapies. ChromaTan’s customer list includes pharmaceutical giants Merck, Roche, and Takeda, in addition to several startups at the cutting edge of biopharmaceutical innovation. The company is working to enable the next generation of gene therapies, antibodies, and nanomedicines. For more information, visit www.chromatan.com.